Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Chief Scientific Officer | September 16, 2024 | September 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date September 16, 2024 · Filed September 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,710 |
Ending reported balance
After 2024-09-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-16 · Exercise / conversion · Acquired 2,250 · Balance 131,371 F1: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Row 2 · 2024-09-16 · Tax withholding · Disposed 661 · Balance 130,710 F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2025-02-28 | Direct | 14,250 |
Reported balance
After 2024-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-16 · Exercise / conversion · Disposed 2,250 · Balance 14,250 F1: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2024 Filed Sep 17, 2024 21:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000081 · wk-form4_1726607530.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 661 | $6.36 | $4,203.96 |
DisclosureSEC source: 0001662579-24-000081 · wk-form4_1726607530.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,710 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000081 · wk-form4_1726607530.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000030 · wk-form4_1709943962.xml · derivative · entry 4 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2032-02-13 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Disposition to issuerStock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001662579-24-000030 · wk-form4_1709943962.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,000 shares Expires 2032-02-13 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 94,950 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000030 · wk-form4_1709943962.xml · derivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,950 Underlying: Common Stock · 94,950 shares Expires 2031-02-10 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Disposition to issuerStock Option (Right to Buy) · Derivative | 94,950 | $0.00 Strike: $45.54 | $0.00 |
DisclosureSEC source: 0001662579-24-000030 · wk-form4_1709943962.xml · derivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,950 shares Expires 2031-02-10 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 122,800 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001662579-24-000016 · wk-form4_1708034642.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,800 Underlying: Common Stock · 122,800 shares Expires 2034-02-13 F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 27,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000016 · wk-form4_1708034642.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,121 F2 · shares: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 2,255 | $6.53 | $14,725.15 |
DisclosureSEC source: 0001662579-24-000016 · wk-form4_1708034642.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,821 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 23:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000100 · wk-form4_1695165800.xml · derivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000082 · wk-form4_1693512618.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 661 | $2.93 | $1,936.73 |
DisclosureSEC source: 0001662579-23-000082 · wk-form4_1693512618.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,076 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000082 · wk-form4_1693512618.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:46 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001662579-23-000039 · wf-form4_167649755275761.xml · derivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:46 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000039 · wf-form4_167649755275761.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,487 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000018 · wf-form4_167528571311726.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,301 | $7.78 | $10,121.78 |
DisclosureSEC source: 0001662579-23-000018 · wf-form4_167528571311726.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,487 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000018 · wf-form4_167528571311726.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036715 · doc4a.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,038 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032511 · doc4.xml · derivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032511 · doc4.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 00:41 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,928 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-22-024228 · doc4.xml · derivative · entry 4 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,152 Underlying: Common Stock · 25,928 shares Expires 2030-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests and becomes exercisable in 20 equal quarterly installments, with the first installment vested on September 5, 2020. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 00:41 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,156 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001209191-22-024228 · doc4.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,572 Underlying: Common Stock · 2,156 shares Expires 2028-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 00:41 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 25,928 | $4.98 | $129,121.44 |
DisclosureSEC source: 0001209191-22-024228 · doc4.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 00:41 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,156 | $3.71 | $7,998.76 |
DisclosureSEC source: 0001209191-22-024228 · doc4.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantPerformance Restricted Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010208 · doc4.xml · derivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-02-28 F2 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F2 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-22-010208 · doc4.xml · derivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2032-02-13 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 403 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-21-069036 · doc4.xml · derivative · entry 6 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,994 Underlying: Common Stock · 403 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,786 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001209191-21-069036 · doc4.xml · derivative · entry 5 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,728 Underlying: Common Stock · 17,786 shares Expires 2028-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,373 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-069036 · doc4.xml · derivative · entry 4 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,373 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 403 | $4.98 | $2,006.94 |
DisclosureSEC source: 0001209191-21-069036 · doc4.xml · nonDerivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 17,786 | $3.71 | $65,986.06 |
DisclosureSEC source: 0001209191-21-069036 · doc4.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,373 | $2.11 | $5,007.03 |
DisclosureSEC source: 0001209191-21-069036 · doc4.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:34 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 17,057 | $45.01 | $767,812.33 |
DisclosureSEC source: 0001209191-21-050055 · doc4.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,744 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 22:46 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 18,104 | $45.00 | $814,756.04 |
DisclosureSEC source: 0001209191-21-049116 · doc4.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,801 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:46 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 50,211 | $45.00 | $2,259,630.57 |
DisclosureSEC source: 0001209191-21-049116 · doc4.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,905 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.085. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 94,950 | $0.00 Strike: $45.54 | $0.00 |
DisclosureSEC source: 0001209191-21-010710 · doc4.xml · derivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,950 Underlying: Common Stock · 94,950 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 21:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,929 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001209191-21-007740 · doc4.xml · derivative · entry 8 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,514 Underlying: Common Stock · 5,929 shares Expires 2028-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Form 3 filed on October 1, 2020 included an incorrect exercise price in Table II, Column 2 ($3.72). F3 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on April 24, 2018. The terms of the original grant provide that 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 21:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,371 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-007740 · doc4.xml · derivative · entry 7 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,371 Underlying: Common Stock · 2,371 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 20% of this option vested and became exercisable on May 2, 2017, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 21:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 5,929 | $3.71 | $21,996.59 |
DisclosureSEC source: 0001209191-21-007740 · doc4.xml · nonDerivative · entry 4 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Form 3 filed on October 1, 2020 included an incorrect exercise price in Table II, Column 2 ($3.72). Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 21:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,371 | $2.11 | $5,002.81 |
DisclosureSEC source: 0001209191-21-007740 · doc4.xml · nonDerivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2020 Filed Feb 4, 2021 21:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,701 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001209191-21-007740 · doc4.xml · derivative · entry 6 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,443 Underlying: Common Stock · 9,701 shares Expires 2028-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Form 3 filed on October 1, 2020 included an incorrect exercise price in Table II, Column 2 ($3.72). F3 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on April 24, 2018. The terms of the original grant provide that 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| December 11, 2020 Filed Feb 4, 2021 21:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,743 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-007740 · doc4.xml · derivative · entry 5 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,742 Underlying: Common Stock · 4,743 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 20% of this option vested and became exercisable on May 2, 2017, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| December 11, 2020 Filed Feb 4, 2021 21:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 9,701 | $3.71 | $35,990.71 |
DisclosureSEC source: 0001209191-21-007740 · doc4.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Form 3 filed on October 1, 2020 included an incorrect exercise price in Table II, Column 2 ($3.72). Read SEC document |
| December 11, 2020 Filed Feb 4, 2021 21:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 4,743 | $2.11 | $10,007.73 |
DisclosureSEC source: 0001209191-21-007740 · doc4.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.